相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives
Frederik A. Verburg et al.
HORMONE AND METABOLIC RESEARCH (2021)
Risk for Thyroid Cancer Recurrence Is Higher in Men Than in Women Independent of Disease Stage at Presentation
Afshan Zahedi et al.
THYROID (2020)
Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
Jonathan K. Kish et al.
ADVANCES IN THERAPY (2020)
New Therapies for Advanced Thyroid Cancer
Diprajan Laha et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
Maria San Roman Gil et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016
Ann E. Powers et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence
Sona Shah et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Differentiated Thyroid Cancer-Treatment: State of the Art
Benedikt Schmidbauer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies
Roy Lirov et al.
DRUGS (2017)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Controlling escape from angiogenesis inhibitors
Barbara Sennino et al.
NATURE REVIEWS CANCER (2012)
分享论文
